Haematology News and Research

RSS

GenomePooling™ method is sensitive and accurate

Population Genetics Technologies Ltd., creator of innovative methods for genetic analyses and biomarker discovery, has successfully completed a pilot study to prove that its GenomePooling™ method is sensitive and accurate enough to detect even small percentages of gene variants within cancer tissue.

31 Jul 2012

Researchers describe new human tissue dendritic cell with cross-presenting function

Researchers in Newcastle and Singapore have identified a new type of white blood cell which activates a killing immune response to an external source - providing a new potential target for vaccines for conditions such as cancer or Hepatitis B.

30 Jul 2012

Updated data from ARIAD’s ponatinib pivotal trial on CML or Ph+ ALL

ARIAD Pharmaceuticals, Inc. today announced updated clinical data from the pivotal PACE trial of its investigational pan-BCR-ABL inhibitor, ponatinib, in patients with chronic myeloid leukaemia (CML) or Philadelphia-positive acute lymphoblastic leukaemia (Ph+ ALL), who are resistant or intolerant to dasatinib or nilotinib or who have the T315I mutation.

18 Jun 2012

Promising results from single iron dose study for fatigue treatment in iron deficient women

Dr Micheal Hedenus of the Haematology Unit of the Sundsval Hospital in Sweden will present promising results on a study on a single iron dose for fatigue treatment in iron deficient women at the 17th Congress of the European Hematology Association in Amsterdam.

From CSL Ltd 16 Jun 2012

Aeterna Zentaris announces results from perifosine Phase 1 trial on multiple myeloma

Aeterna Zentaris Inc. today announced that Phase 1 trial results for the Company's oral anticancer compound, perifosine, in multiple myeloma, have been published in the online May 2012 issue of the British Journal of Haematology.

6 Jun 2012

Skin cancer drug may prolong survival in advanced cases: Study

Researchers say 132 patients in the U.S. and Australia who were given the drug vemurafenib gained several extra months of life. The study published in the New England Journal of Medicine found that those on the drug lived an average of 16 months, compared with nine months on conventional treatment.

26 Feb 2012

New details about how cell signalling is controlled in immune system

Walter and Eliza Hall Institute scientists have revealed new details about how cell signalling is controlled in the immune system, identifying in the process potential new therapeutic targets for treating severe blood disorders.

17 Feb 2012

Progenitor cells have potential to develop into RBCs

A study of the cells that respond to crises in the blood system has yielded a few surprises, redrawing the 'map' of how blood cells are made in the body.

1 Feb 2012

'Pro-survival' protein inhibitors may improve outlook for AML patients

Melbourne researchers have discovered that acute myeloid leukaemia (AML), an aggressive blood cancer with poor prognosis, may be susceptible to medications that target a protein called Mcl-1.

18 Jan 2012

Researchers discover new tick-borne infection

Researchers at the University of Gothenburg's Sahlgrenska Academy have discovered a brand new tick-borne infection. Since the discovery, eight cases have been described around the world, three of them in the Gothenburg area, Sweden.

7 Dec 2011

Scientists identify a way that chemotherapy causes platelet numbers to drop

Scientists at the Walter and Eliza Hall Institute have identified a way that chemotherapy causes platelet numbers to drop, answering in the process a decade-old question about the formation of platelets, tiny cells that allow blood to clot.

26 Sep 2011

Researchers use ultrasound to improve quality of blood stem cell transplant

Transplantation of haematopoietic stem cells is an effective treatment for patients with malignant blood diseases. The composition and quality of the transplanted cells are crucial to the outcome. Researchers from Lund University, Sweden, have now developed a method to improve the quality of the transplanted cells using ultrasound for cell separation.

7 Sep 2011

Golden Meditech launches Taiwan representative office

Golden Meditech Holdings Limited, which embodies a leading medical devices enterprise, a major brand name in haematology hospital and the largest stem cell cord blood banking operator in China, is pleased to announce the launch of its Taiwan representative office today.

6 Sep 2011

Golden Meditech total turnover increases 15% to HK$328,066,000 for year ended 31 March, 2011

Golden Meditech Holdings Limited, a leading integrated healthcare enterprise in China, is pleased to announce the Group's annual results for the year ended 31 March, 2011.

30 Jun 2011

GM Hospital Group acquires Beijing hospital facility for HK$600,000,000

Golden Meditech Holdings Limited, is pleased to announce the acquisition of a hospital facility in Beijing's Haidian District for a total consideration of HK$600,000,000.

28 Jun 2011

Spectrum announces various clinical studies on ZEVALIN at ICML 2011

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, today announced that various studies on ZEVALIN for Injection were presented at the 11th International Conference on Malignant Lymphoma (ICML), held June 15-18, 2011, in Lugano, Switzerland.

20 Jun 2011

Celgene, GELA to conduct REVLIMID/rituximab combination study on newly diagnosed FL

Groupe d'Etude des Lymphomes de l'Adulte (GELA) and Celgene International Sarl today announced a collaboration to conduct an international randomized study to evaluate the therapeutic potential of the REVLIMID/rituximab combination regimen (R2) in patients with newly diagnosed follicular lymphoma.

17 Jun 2011